Get started
Author

Lucía Santomé Couto

Observed names: L Santomé Couto, L. Santomé Couto, L. Santomé-Couto, Lucia Santome-Couto, Lucia Santomé Couto, Lucía Santomé-Couto, Santomé Couto L, Santomé Couto Lucía
Institution: Povisa Hospital
ORCID: 0000-0002-0339-5218
Observed ORCID: 0000-0002-0339-5218
OpenAlex ID: A5007179647
Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience
2018 · Mª Carmen Areses Manrique, Joaquín Mosquera Martínez, et al. · Translational Lung Cancer Research · 64
PDF
Guía de práctica clínica
2007 · José Abal Arca, Francisco Javier Barón Duarte, et al. · 59
PD-(L)1 Inhibitors in Combination with Chemotherapy as First-Line Treatment for Non-Small-Cell Lung Cancer: A Pairwise Meta-Analysis
2020 · Jorge García-González, Juan Ruiz-Bañobre, et al. · Journal of Clinical Medicine · 29
PDF
Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer
2024 · Urbano Anido-Herranz, Ovidio Fernandez-Calvo, et al. · Frontiers in Oncology · 10
Prostate cancer perspectives after chaarted: Optimizing treatment sequence
2016 · Sergio Vázquez Estévez, Urbano Anido Herranz, et al. · Critical Reviews in Oncology/Hematology · 8
Efficacy and safety of Nivolumab in older patients with pretreated lung cancer: A subgroup analysis of the Galician lung cancer group
2020 · David Arias Ron, Maria Carmen Areses Manrique, et al. · Journal of Geriatric Oncology · 7
PDF
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
2018 · U. Anido-Herranz, N. Fernández-Núñez, et al. · Clinical & Translational Oncology · 5
PDF
[Diagnosis and management of carcinoma in situ of the testis].
2000 · V Valentí Moreno, J Tabernero Caturla, et al. · PubMed · 4
Mycophenolate mofetil as a treatment of severe steroid-resistant immune-related hepatitis
2021 · Cristina Macía-Rodríguez, Lucia Santomé Couto, et al. · Gastroenterología y Hepatología · 3
Assessment of efficacy, safety, and prognostic/predictive factors of nintedanib/docetaxel in advanced/recurrent non–small cell lung cancer post-immunotherapy and chemotherapy: A Galician Lung Cancer Group study
2025 · Natalia Fernández Núñez, Martín Lázaro Quintela, et al. · Cancer Treatment and Research Communications · 1
[Translated article] Real-world evidence of immune-related adverse events as predictive factor of response in non-small cell lung cancer
2026 · Maria Susana Fortes-Gonzalez, Silvia Vazquez-Blanco, et al. · Farmacia Hospitalaria
Efectos adversos inmunorrelacionados como factor predictivo de respuesta en cáncer de pulmón no microcítico en vida real
2026 · Maria Susana Fortes-Gonzalez, Silvia Vazquez-Blanco, et al. · Farmacia Hospitalaria
Clinical outcomes and survival in patients with NSCLC and EGFR exon 20 mutations: evidence from real-world clinical practice in a retrospective study in Galicia
2026 · Begoña Campos Balea, Martín Emilio Lázaro Quintela, et al. · Frontiers in Oncology
PDF
Efficacy and safety of first-line pemetrexed plus carboplatin followed by pemetrexed maintenance in newly diagnosed and metastatic elderly non-squamous Non-Small Cell Lung Cancer (NSCLC): Real World Data (RWD) of a Galician and Mediterranean lung cancer group
2025 · Arias Ron David, Álvarez Fernández Javier, et al. · Cancer Treatment and Research Communications
Neutropenia febril
2020 · María Mar Cutillas-Pérez, Cristina Macía-Rodríguez, et al. · Revista Española de Casos Clínicos en Medicina Interna
Immune checkpoint inhibitors (ICI) in combination with chemotherapy as first-line (1L) treatment for non-small cell lung cancer (NSCLC): A pair-wise meta-analysis (MA)
2019 · F.J. Afonso-Afonso, M. Amenedo Gancedo, et al. · Annals of Oncology
Sunitinib in Special Situations in their Daily Practice
2016 · Molina Díaz A, Afonso Afonso Fj, et al. · Clinics in Oncology
Guía de práctica clínica. Cancro de pulmón e mesotelioma
2007 · José Abal Arca, Francisco Javier Barón Duarte, et al. · Dialnet (Universidad de la Rioja)
Works count: 18
Citation count: 190
H-index: 6
I10-index: 4
Year
Topic
Type